Abstract
Context: Thyroid carcinoma is one of the mostcommonmalignancies of the endocrine system, and, despite the high frequency of oncogene activation in thyroid neoplastic lesions, the tumor suppressor genes involved in thyroid carcinogenesis remain unidentified.Ourprevious data implicated a link between the CL2/CCDC80 gene and thyroid cancer. Objective: The objective of the study was to examine the expression of the CL2/CCDC80 gene in human thyroid carcinomas in the attempt to determine whether it plays a role in thyroid carcinogenesis. Design: Weevaluated the expression of CL2/CCDC80 in a large number of thyroid neoplastic tissue samples differing in degree of malignancy. We also investigated the effects of its restoration in 2 human thyroid carcinoma cell lines characterized by very low levels of CL2/CCDC80 expression. Results: CL2/CCDC80 expression was much lower in almost all the thyroid carcinomas analyzed than in normal thyroid tissues and was lowest in follicular variants of papillary carcinomas. Loss of heterozygosity partially accounted for CL2/CCDC80 down-regulation in thyroid carcinoma samples. Restoration of CL2/CCDC80 expression in the 2 human thyroid anaplastic carcinoma cell lines resulted in a higher susceptibility to apoptosis and suppression of the malignant phenotype. CL2/CCDC80 expression positively regulated the expression of E-cadherin, thereby halting cancer progression. Conclusions: These results indicate that CL2/CCDC80 is a putative tumor suppressor gene in thyroid carcinogenesis.
| Original language | English |
|---|---|
| Pages (from-to) | 2834-2843 |
| Number of pages | 10 |
| Journal | Journal of Clinical Endocrinology and Metabolism |
| Volume | 98 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2013 |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Clinical Biochemistry
- Endocrinology
- Biochemistry, medical
- Endocrinology, Diabetes and Metabolism
Cite this
Tumor suppressor role of the CL2/DRO1/CCDC80 gene in thyroid carcinogenesis. / Ferraro, Angelo; Schepis, Filippo; Leone, Vincenza; Federico, Antonella; Borbone, Eleonora; Pallante, Pierlorenzo; Berlingieri, Maria Teresa; Chiappetta, Gennaro; Monaco, Mario; Palmieri, Dario; Chiariotti, Lorenzo; Santoro, Massimo; Fusco, Alfredo.
In: Journal of Clinical Endocrinology and Metabolism, Vol. 98, No. 7, 07.2013, p. 2834-2843.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tumor suppressor role of the CL2/DRO1/CCDC80 gene in thyroid carcinogenesis
AU - Ferraro, Angelo
AU - Schepis, Filippo
AU - Leone, Vincenza
AU - Federico, Antonella
AU - Borbone, Eleonora
AU - Pallante, Pierlorenzo
AU - Berlingieri, Maria Teresa
AU - Chiappetta, Gennaro
AU - Monaco, Mario
AU - Palmieri, Dario
AU - Chiariotti, Lorenzo
AU - Santoro, Massimo
AU - Fusco, Alfredo
PY - 2013/7
Y1 - 2013/7
N2 - Context: Thyroid carcinoma is one of the mostcommonmalignancies of the endocrine system, and, despite the high frequency of oncogene activation in thyroid neoplastic lesions, the tumor suppressor genes involved in thyroid carcinogenesis remain unidentified.Ourprevious data implicated a link between the CL2/CCDC80 gene and thyroid cancer. Objective: The objective of the study was to examine the expression of the CL2/CCDC80 gene in human thyroid carcinomas in the attempt to determine whether it plays a role in thyroid carcinogenesis. Design: Weevaluated the expression of CL2/CCDC80 in a large number of thyroid neoplastic tissue samples differing in degree of malignancy. We also investigated the effects of its restoration in 2 human thyroid carcinoma cell lines characterized by very low levels of CL2/CCDC80 expression. Results: CL2/CCDC80 expression was much lower in almost all the thyroid carcinomas analyzed than in normal thyroid tissues and was lowest in follicular variants of papillary carcinomas. Loss of heterozygosity partially accounted for CL2/CCDC80 down-regulation in thyroid carcinoma samples. Restoration of CL2/CCDC80 expression in the 2 human thyroid anaplastic carcinoma cell lines resulted in a higher susceptibility to apoptosis and suppression of the malignant phenotype. CL2/CCDC80 expression positively regulated the expression of E-cadherin, thereby halting cancer progression. Conclusions: These results indicate that CL2/CCDC80 is a putative tumor suppressor gene in thyroid carcinogenesis.
AB - Context: Thyroid carcinoma is one of the mostcommonmalignancies of the endocrine system, and, despite the high frequency of oncogene activation in thyroid neoplastic lesions, the tumor suppressor genes involved in thyroid carcinogenesis remain unidentified.Ourprevious data implicated a link between the CL2/CCDC80 gene and thyroid cancer. Objective: The objective of the study was to examine the expression of the CL2/CCDC80 gene in human thyroid carcinomas in the attempt to determine whether it plays a role in thyroid carcinogenesis. Design: Weevaluated the expression of CL2/CCDC80 in a large number of thyroid neoplastic tissue samples differing in degree of malignancy. We also investigated the effects of its restoration in 2 human thyroid carcinoma cell lines characterized by very low levels of CL2/CCDC80 expression. Results: CL2/CCDC80 expression was much lower in almost all the thyroid carcinomas analyzed than in normal thyroid tissues and was lowest in follicular variants of papillary carcinomas. Loss of heterozygosity partially accounted for CL2/CCDC80 down-regulation in thyroid carcinoma samples. Restoration of CL2/CCDC80 expression in the 2 human thyroid anaplastic carcinoma cell lines resulted in a higher susceptibility to apoptosis and suppression of the malignant phenotype. CL2/CCDC80 expression positively regulated the expression of E-cadherin, thereby halting cancer progression. Conclusions: These results indicate that CL2/CCDC80 is a putative tumor suppressor gene in thyroid carcinogenesis.
UR - http://www.scopus.com/inward/record.url?scp=84879967532&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879967532&partnerID=8YFLogxK
U2 - 10.1210/jc.2012-2926
DO - 10.1210/jc.2012-2926
M3 - Article
VL - 98
SP - 2834
EP - 2843
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 7
ER -